论文部分内容阅读
目的探讨高危型人乳头瘤状病毒(HPV)DNA16、18检测在宫颈病变筛查的临床价值。方法对妇科门诊875例慢性宫颈炎患者均采用HC2方法检测HPV-DNA16、18,同时进行阴道镜下活检组织病理学检查,以病理学诊断为金标准。结果875例妇女患者,HPV16、18阳性者有259例,占29.6%。经阴道镜下定位活检病理确诊患者中HPV16、18阳性率分别为慢性宫颈炎15.5%(80/515),宫颈湿疣38.7%(74/191),宫颈上皮内瘤变CINⅠ型61.9%(39/63),CINⅡ型58.7%(44/75),CINⅢ型62.5%(15/24),宫颈癌100%(7/7)。CINⅠHPV感染率高于CINⅡ(P<0.05),具有显著性差异。结论HC2-HPV-DNA检测为一种先进有效的宫颈病变的筛查方法,具有积极的意义。
Objective To investigate the clinical value of high-risk human papillomavirus (HPV) DNA16,18 in screening cervical lesions. Methods 875 cases of chronic cervicitis in gynecology clinic were detected by HC2 method of HPV-DNA16,18, colposcopic biopsy histopathological examination, the pathological diagnosis as the gold standard. Results Among 875 women, 259 were positive for HPV16 and 18, accounting for 29.6%. The positive rates of HPV16 and HPV16 in pathologically confirmed colposcopic biopsy were 15.5% (80/515), 38.7% (74/191), 61.9% (39.9%) of cervical intraepithelial neoplasia, 63), CIN II type 58.7% (44/75), CIN III type 62.5% (15/24) and cervical cancer 100% (7/7). The infection rate of CINⅠHPV was higher than that of CINⅡ (P <0.05), with significant difference. Conclusion HC2-HPV-DNA test is an advanced and effective screening method for cervical lesions, which has positive significance.